Physiopathology and Pharmacology of the Gastrointestinal Tract

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 1951

Special Issue Editor


E-Mail Website
Guest Editor
Department of Basic Health Sciences, Faculty of Health Sciences, Rey Juan Carlos University (URJC), Alcorcón, 28922 Madrid, Spain
Interests: gastrointestinal motility; visceral pain; functional foods; cannabinoids; irritable bowel syndrome; nutraceuticals; enteric nervous system; brain–gut axis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The gastrointestinal (GI) tract is a tubular system that comprises different organs from the mouth to anus and is widely known for its key role in food digestion and nutrient absorption. However, it plays a key role in many other essential functions, including acting as a physical barrier and endocrine and immune surveillance. It is a complex system whose wall is home to many different cell types organized in different layers: mucosa, submucosa, muscle layers, and serosa. The GI tract is intrinsically innervated by the enteric nervous system, comprising both neurons and glial cells in two plexuses, submucous and myenteric, with the latter regulating its motor function with the aid of pacemaker cells (interstitial cells of Cajal). Furthermore, it is also connected to the central nervous system through the parasympathetic and sympathetic branches of the autonomic nervous system, giving rise to the concept of the “brain–gut axis”, to which the hormonal influences and those of the gut microbiota also contribute. The GI tract and the brain–gut axis are considered essential for homeostasis and many factors may affect them, causing specific symptoms, diseases and disorders that need adequate treatments. In the last few years, the GI tract (and the brain–gut axis) has attracted much attention, and many researchers are looking at it in renewed and pluridisciplinary ways in order to improve the understanding of its physiopathology and to increase the offer of pharmacological tools to treat the conditions that affect it.

Thus, this Special Issue aims to collect high-quality manuscripts (preclinical and translational studies, reviews, systematic reviews, meta-analyses…) focused on the GI tract, its physiology, the diseases and disorders that affect it or affect the brain–gut axis, and, specially, new pharmacological approaches to treat them.

Prof. Dr. Raquel Abalo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gastrointestinal (GI) tract
  • brain-gut axis
  • pacemaker cells

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

15 pages, 635 KiB  
Review
The Use and Potential Benefits of N-Acetylcysteine in Non-Acetaminophen Acute Liver Failure: An Etiology-Based Review
by Mihai Popescu, Angelica Bratu, Mihaela Agapie, Tudor Borjog, Mugurel Jafal, Romina-Marina Sima and Carmen Orban
Biomedicines 2024, 12(3), 676; https://doi.org/10.3390/biomedicines12030676 - 18 Mar 2024
Viewed by 1688
Abstract
Acute liver failure represents a life-threatening organ dysfunction with high mortality rates and an urgent need for liver transplantation. The etiology of the disease varies widely depending on various socio-economic factors and is represented mainly by paracetamol overdose and other drug-induced forms of [...] Read more.
Acute liver failure represents a life-threatening organ dysfunction with high mortality rates and an urgent need for liver transplantation. The etiology of the disease varies widely depending on various socio-economic factors and is represented mainly by paracetamol overdose and other drug-induced forms of liver dysfunction in the developed world and by viral hepatitis and mushroom poisoning in less developed countries. Current medical care constitutes either specific antidotes or supportive measures to ensure spontaneous recovery. Although it has been proven to have beneficial effects in paracetamol-induced liver failure, N-acetylcysteine is widely used for all forms of acute liver failure. Despite this, few well-designed studies have been conducted on the assessment of the potential benefits, dose regimens, or route of administration of N-acetylcysteine in non-acetaminophen liver failure. This review aims to summarize the current evidence behind the use of this drug in different forms of liver failure. Full article
(This article belongs to the Special Issue Physiopathology and Pharmacology of the Gastrointestinal Tract)
Show Figures

Figure 1

Back to TopTop